Jointown Pharmaceutical Group Co., Ltd.SSE: 600998

Report for Q1 2026

Apr 28, 2026 · Issued by Jointown Pharmaceutical Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 28, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-245

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Jointown Pharmaceutical Group Co., Ltd. on 6ix

Earlier from Jointown Pharmaceutical

Announcement on Results of Issuing Phase II Ultra-Short-Term Financing Bonds of 2026Apr 24
Announcement on the Subsidiary Receiving the "Acceptance Notice" from the National Medical Products Administration for the Market Application of Azelastine Hydrochloride Nasal SprayApr 22
Announcement on Temporary Idle Funds’ Investment Management Arrangements for Q1 2026Apr 9
Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional InvestorsApr 3
Announcement on Obtaining Medical Device Registration Certificate by Holding SubsidiaryMar 25

Later from Jointown Pharmaceutical

Announcement on Holding Subsidiary Certified as High-tech EnterpriseApr 30
Announcement on Subsidiary's Passing GMP Compliance Inspection for DrugsMay 7
Announcement on Recognition of Subsidiary as High-tech EnterpriseMay 13
Indicative Announcement on Convening the 2025 Annual General MeetingMay 15
Announcement on Resolutions of the 2025 Annual General MeetingMay 22

All Jointown Pharmaceutical news releases

Follow Jointown Pharmaceutical into a list and get an email when it puts out news.

Follow Jointown Pharmaceutical